Prostatic neuroendocrine tumor in multiple endocrine neoplasia Type 2B. 2004

B Goulet-Salmon, and E Berthe, and S Franc, and S Chanel, and F Galateau-Salle, and M Kottler, and J Mahoudeau, and Y Reznik
Department of Endocrinology Hospital CHU, Caen, France. bsalmon@ch-aleucom.fr

We report the unusual occurrence of a neuroendocrine prostatic tumor in two young males with multiple endocrine neoplasia (MEN) 2B. Immunohistochemistry of the tumor markers may help differentiate a primary neuroendocrine prostate tumor from the metastasis of a medullary thyroid carcinoma of poor prognosis. MEN 2B hallmarks (i.e. plasma thyrocalcitonin and urinary metanephrines) may be systematically investigated in neuroendocrine tumors of the prostate, and conversely prostate examination may be performed in the periodic screening of MEN 2B male patients.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008297 Male Males
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D003937 Diagnosis, Differential Determination of which one of two or more diseases or conditions a patient is suffering from by systematically comparing and contrasting results of diagnostic measures. Diagnoses, Differential,Differential Diagnoses,Differential Diagnosis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D018358 Neuroendocrine Tumors Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition. Neuroendocrine Tumor,Tumor, Neuroendocrine,Tumors, Neuroendocrine
D018814 Multiple Endocrine Neoplasia Type 2b Similar to MEN2A, it is also caused by mutations of the MEN2 gene, also known as the RET proto-oncogene. Its clinical symptoms include medullary carcinoma (CARCINOMA, MEDULLARY) of THYROID GLAND and PHEOCHROMOCYTOMA of ADRENAL MEDULLA (50%). Unlike MEN2a, MEN2b does not involve PARATHYROID NEOPLASMS. It can be distinguished from MEN2A by its neural abnormalities such as mucosal NEUROMAS on EYELIDS; LIP; and TONGUE, and ganglioneuromatosis of GASTROINTESTINAL TRACT leading to MEGACOLON. It is an autosomal dominant inherited disease. MEN 2b,MEN 3,Neoplasia, Multiple Endocrine Type 2b,Neoplasms, Multiple Endocrine Type 2b,MEA 2b,MEA IIb,MEN III,MEN IIb,MEN2b,Mucosal Neuroma Syndrome,Multiple Endocrine Neoplasia, Type 2b,Multiple Endocrine Neoplasia, Type IIb,Multiple Endocrine Neoplasms Type 2b,Neuromata, Mucosal, With Endocrine Tumors,Wagenmann-Froboese Syndrome,Mucosal Neuroma Syndromes,Neuroma Syndrome, Mucosal,Syndrome, Wagenmann-Froboese,Wagenmann Froboese Syndrome

Related Publications

B Goulet-Salmon, and E Berthe, and S Franc, and S Chanel, and F Galateau-Salle, and M Kottler, and J Mahoudeau, and Y Reznik
January 2015, Nederlands tijdschrift voor geneeskunde,
B Goulet-Salmon, and E Berthe, and S Franc, and S Chanel, and F Galateau-Salle, and M Kottler, and J Mahoudeau, and Y Reznik
June 1983, Horumon to rinsho. Clinical endocrinology,
B Goulet-Salmon, and E Berthe, and S Franc, and S Chanel, and F Galateau-Salle, and M Kottler, and J Mahoudeau, and Y Reznik
January 1978, Pathobiology annual,
B Goulet-Salmon, and E Berthe, and S Franc, and S Chanel, and F Galateau-Salle, and M Kottler, and J Mahoudeau, and Y Reznik
July 2001, International journal of urology : official journal of the Japanese Urological Association,
B Goulet-Salmon, and E Berthe, and S Franc, and S Chanel, and F Galateau-Salle, and M Kottler, and J Mahoudeau, and Y Reznik
May 2017, Federal practitioner : for the health care professionals of the VA, DoD, and PHS,
B Goulet-Salmon, and E Berthe, and S Franc, and S Chanel, and F Galateau-Salle, and M Kottler, and J Mahoudeau, and Y Reznik
July 2021, QJM : monthly journal of the Association of Physicians,
B Goulet-Salmon, and E Berthe, and S Franc, and S Chanel, and F Galateau-Salle, and M Kottler, and J Mahoudeau, and Y Reznik
May 1998, AJR. American journal of roentgenology,
B Goulet-Salmon, and E Berthe, and S Franc, and S Chanel, and F Galateau-Salle, and M Kottler, and J Mahoudeau, and Y Reznik
January 1982, Histopathology,
B Goulet-Salmon, and E Berthe, and S Franc, and S Chanel, and F Galateau-Salle, and M Kottler, and J Mahoudeau, and Y Reznik
January 2000, Ryoikibetsu shokogun shirizu,
B Goulet-Salmon, and E Berthe, and S Franc, and S Chanel, and F Galateau-Salle, and M Kottler, and J Mahoudeau, and Y Reznik
January 1978, Endokrynologia Polska,
Copied contents to your clipboard!